Evaluation of Soluble CD30 as an Immunologic Marker in Heart Transplant Recipients

Transplantation Proceedings

Volumn 38, Issue 10, 2006, Pages 3689-3691

  Spiridon, C ^a   Hunt, J ^b   Mack, M ^b   Rosenthal, J ^b   Anderson, A ^b   Eichhorn, E ^b   Magee, M ^b   Dewey, T ^b   Currier, M ^b   Nikaein, A ^a  

^a Texas Medical Specialty Inc   (United States)

^b MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN ANTIBODY;

ARTICLE; CYTOTOXICITY; GRAFT INFECTION; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HUMAN CELL; IMMUNOASSAY; INFECTION CONTROL; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD30; BIOLOGICAL MARKERS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33845456655     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.10.088     Document Type: Article

References (16)

1. Claas F.J.H., Van Leewen A., and Van Rood J. Hyperimmunized patients do not need to wait for an HLA identical donor. Tissue Antigens 34 (1999) 23
2. Laundy G.L., and Bradley B.A. The predictive value of epitope analysis in highly sensitised patients awaiting renal transplantation. Transplantation 59 (1995) 1207
3. Gebel H.M., and Brag R.A. Sensitization and sensitivity. Defining unsensitized patients. Transplantation 69 (2000) 1370
4. Kerman R., Orosz C., and Lorber M. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci 313 (1997) 275
5. Aizawa S., Nakano H., Horie R., et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF 2 are involved in CD30-mediated NF-kappa-B activation. J Biol Chem 272 (1997) 2042
6. Soo Y.L., Sang Y.L., Gokul K., et al. CD30/TNF receptor associated factor interaction: NF-kB activation and binding specificity. Proc Natl Acad Sci USA 93 (1996) 9699
7. Martinez Olivia M., Villanueva J., Abtahi S., et al. CD30 expression identifies a functional alloreactive human T lymphocyte subset. Transplantation 65 (1998) 1240
8. Schneider C., and Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leukemia Lymph 43 (2002) 1355
9. Ansieau S., Scheffrahn I., Mosialos G., et al. Tumor necrosis factor receptor-associated factor (TRAF)1, TRAF-2. Proc Natl Acad Sci USA 93 (1996) 14053
10. Bauwens A.M., van de Graaf E.A., van Ginkel W.G., et al. Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transpl 25 (2006) 416
11. Bertollo A., Vagliasindi C., Gerli R., et al. Soluble CD30 antigen in human colostrums. Biol Neonate 71 (1997) 69
12. Strom T.B., Roy-Chaudhury P., Manfro R., et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 8 (1996) 688
13. Susal C., Pelzl S., Simon T., et al. Advances in pre- and post-transplant immunologic testing in kidney transplantation. Transplant Proc 36 (2004) 29
14. Susal C., Pelzl S., and Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 76 (2003) 1231
15. Weimer R., Zipperle S., Daniel V., et al. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation 62 (1996) 1606
16. Frisaldi E., Conca R., Magistroni P., et al. Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation. Transplantation 81 (2006) 1153